Could a diabetes pill help you breathe better at night?

NCT ID NCT05612594

Recruiting now Symptom relief Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether bexagliflozin, a drug used for diabetes, can reduce the severity of obstructive sleep apnea in overweight or obese adults. Over 6 months, participants will take either the drug or a placebo and undergo sleep tests and body scans. The goal is to see if the drug improves breathing during sleep and reduces related health risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bexagliflozin
What this could lead to: If it works, this could offer a new medication option to reduce sleep apnea severity in people who are overweight.
What could go wrong: This is a relatively small, early-phase trial, and the drug may not significantly improve sleep apnea. Side effects from SGLT2 inhibitors are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE SLEEP APNEA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obstructive sleep apnea syndrome sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SLEEP APNEA

Contacts and locations

Locations

University Hospitals Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States
Yale New Haven Health
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.